BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright ©The Author(s) 2026.
World J Gastrointest Endosc. Jan 16, 2026; 18(1): 114791
Published online Jan 16, 2026. doi: 10.4253/wjge.v18.i1.114791
Table 1 Baseline characteristics of the propensity-matched groups, mean ± SD
Indicator
LPD group (n = 50)
OPD group (n = 50)
t/χ2
P value
Gender (male/female)27/2326/240.020.89
Age (years)62.5 ± 7.263.1 ± 6.8-0.490.62
BMI (kg/m2)24.2 ± 3.124.5 ± 3.0-0.520.61
Tumor size (cm)2.8 ± 0.92.9 ± 1.0-0.380.71
ASA score (I/II/III)2/34/141/35/140.450.80
Diabetes (no/yes)36/1435/150.050.82
Table 2 Perioperative outcomes, mean ± SD
Indicator
LPD group (n = 50)
OPD group (n = 50)
t/χ2
P value
MD/OR (95%CI)
Operative time (minutes)320 ± 45285 ± 404.12< 0.001MD 35 (18.31 to 51.69)
Blood loss (mL)180 ± 60350 ± 90-11.2< 0.001MD -170 (-199.98 to -140.02)
Transfusion (no/yes)46/439/114.650.03OR 0.31 (0.09 to 1.05)
LOS (days)12 ± 315 ± 4-3.280.002MD -3 (-4.39 to -1.61)
Overall complications (no/yes)29/2125/250.680.41OR 0.72 (0.33 to 1.59)
Severe complications (CD ≥ III, no/yes)42/839/110.770.38OR 0.68 (0.25 to 1.85)
Pancreatic fistula (no/yes)44/642/80.320.58OR 0.72 (0.23 to 2.24)
DGE (no/yes)45/543/70.410.52OR 0.68 (0.20 to 2.32)
90-day readmission (no/yes)49/147/31.020.30OR 0.32 (0.03 to 3.18)
90-day mortality (no/yes)49/148/20.240.62OR 0.49 (0.04 to 5.58)
Table 3 Oncologic outcomes, mean ± SD
Indicator
LPD group (n = 50)
OPD group (n = 50)
t/χ2
P value
MD/OR/HR (95%CI)
Lymph nodes retrieved14 ± 513 ± 40.750.45MD 1 (-0.77 to 2.77)
R0 resection (no/yes)4/466/440.340.56OR 1.57 (0.41 to 5.93)
Median OS [months (95%CI)]22 (19-25)20 (17-23)0.65HR 0.92 (0.65 to 1.31)
12-month RFS (%)78720.48HR 0.78 (0.35 to 1.74)
Adjuvant completion (no/yes)8/42 (84%)10/40 (80%)0.240.62OR 1.31 (0.47 to 3.66)